CG Capital
Corporate access · Capital markets advisory

The investors your sell-side isn’t introducing.

We introduce public companies to new investors and book the meetings: family offices and emerging managers outside the usual NDR circuit, for companies of any size in any sector.

The outreach program at a glance. Investors contacted, replies and meetings booked, tracked for every client.

Coverage fills the calendar. It rarely widens the shareholder base.

Bank-led roadshows and conferences keep circling the same funds. The investors who move quickly, family offices and emerging managers across the country, are rarely on the invite list.

Sell-side coverage reaches the investors it already knows. We reach the ones it doesn’t.

A sales desk for the investors the banks don’t reach.

A small senior team that learns your story, finds the right holders and turns interest into meetings. We work alongside your IR firm, not in place of it.

  1. 1

    A story investors can repeat

    You leave the teach-in with sharper messages, a snapshot, peer comparables and a tear sheet for every meeting, so each investor hears the same clear case.

  2. 2

    Introductions to investors who don’t know you yet

    We screen for funds that fit your peers and shareholder base, and remove existing holders and known names. You get family offices and emerging managers who are new to the stock.

    13F cross-checks · peer holders · family offices nationwide
  3. 3

    Meetings on your calendar

    We run the email and phone outreach and book the meetings for you. Monthly reporting shows what is landing, and we adjust the message as we learn.

Corporate access

Meetings that are prepared for

Investor meetings, conferences and management days, scheduled for you, with a tear sheet on every investor before you sit down.

Media amplification

Reach beyond your own list

Your news and research get in front of investors who aren’t already on your distribution list.

Microcap Healthcare Weekly

A weekly read investors open

Our weekly market read on micro and small-cap healthcare, sent to the investors we work with. It keeps CG in front of them every week.

IPO & transaction advisory

Investor demand, before you price

We bring investor feedback and introductions into your IPO, follow-on or private placement, so the book is built with the right holders in mind.

Frontline investor management

We take the tough calls

When investors push back or ask hard questions, we handle the conversation with them directly and bring you what matters, so management time goes where it counts.

Start with a structured pilot. A defined scope, deliverables and evaluation metrics: a low-risk way to validate the approach before a broader commitment.

Talk through a pilot
“CG is incredibly well connected with an amazing work ethic. The team consistently comes up with effective, creative solutions.”
Dan GoldbergerChief Executive Officer, electroCore, Inc.
“It quickly helped us take a fresh approach to communicate our story with the right audience.”
Steve ArmondChief Financial Officer, Health TrackRx
“I have seen him in the toughest of times assist CEOs and other C-suite execs in putting their best foot forward with investors.”
Mike PetuskyResearch Analyst, Barrington Research Associates
The team

Senior people doing the work.

You’ll know who’s calling investors on your behalf, because it’s the same people you met.

Rich Cockrell

Rich Cockrell

Founder

Founded CG Capital in 2008 after a career as a Wall Street equity analyst at UBS and Jefferies and in senior investor relations and finance roles at The Home Depot, El Paso Energy, ING Americas, Matria Healthcare and KCI. His work has led to over $500 million in financings.

Joy Willis

Joy Willis

Director

Investor relations professional with nearly a decade across leading IR agencies and in-house roles. Leads investor outreach, targeting and reporting, and manages relationships with C-suite teams and institutional investors.

Eric Beder

Eric Beder

Equity analyst

Equity research analyst for over twenty years at Ladenburg Thalmann, Brean Murray, Wunderlich and B. Riley/FBR, covering consumer, technology, medical and mining. Three-time Wall Street Journal Best on the Street winner.

Proof

From large-cap to micro-cap, the same method.

Three issuers across the size range: a large-cap issuer’s meeting calendar matched against our targeting universe, a small-cap issuer’s meetings over thirteen months, and a micro-cap issuer’s outreach funnel from the start of its program. Size bands reflect each issuer’s current market capitalization.

Large-cap issuer · $10B+ market cap
Industrials

Where our targeting meets a real meeting calendar.

Sixteen months of the issuer’s investor meetings (April 2025 to August 2026), compared firm by firm with the investors we target.

Investment firms the issuer met directly208
78 already in our targeting universe (37.5%)130 not yet in it
1,163firms in our dedicated targeting universe
1,085firms in that universe the issuer has not yet met: the opportunity
Small-cap issuer · $300M–$2B market cap
Healthcare

Meetings that kept coming, not only in conference week.

Investor meetings held for the issuer from January 2024 to January 2025, by month. Most took place outside the January conference weeks.

JanFebMarAprMayJunJulAugSepOctNovDecJan

January conference weeks   All other months

60investor meetings held
59different investment firms
36meetings outside conference weeks
Micro-cap issuer · under $300M market cap
Medical technology

From outreach to meetings, tracked end to end.

The program began in October 2025 and continues past its initial term. Meetings span institutions, hedge funds, family offices, private equity and venture investors.

  • 12,068
  • ~200
  • 48
  • 36
  • Top to bottom: investors reached, personal replies (estimate, automated replies excluded), meetings requested, meetings held. Bar lengths are illustrative, not to scale.
Technology · How we find them

Targeting built on twenty years of investor data.

Ownership, meeting and outreach history collected since 2008 feeds the models. Every client sees the results in their own portal.

How we find them · illustrationRanked targets
  1. 01Full investor universe
  2. 02Fit against peer-holder profiles
  3. 03Existing holders and known names removed
  4. 04Ranked, unmet targets
  • 1Family office · SoutheastHigh fit
  • 2Emerging manager · NortheastHigh fit
  • 3Family office · MidwestHigh fit
  • 4Emerging manager · WestHigh fit

Illustrative only. Each dot is an investor; names, counts and scores are not real.

Two decadesof data Screeningmodels Rankedtargets Meetingsbooked Live clientportal

Two decades of data

Ownership filings, peer-holder patterns, past outreach and meeting outcomes, kept current so every engagement starts from what has already worked.

Models that find the fit

Fit scoring against peer-holder profiles surfaces the funds that belong in your stock and are not in it yet.

Your portal and investor page

A private portal refreshed every weekday after the close, plus a dedicated investor page that gives prospects one place to learn the story.

The fastest-growing pool of long-duration capital.

Family offices run flexible mandates, hold for the long term, and are on track to manage assets that rival hedge funds. Traditional distribution still under-reaches them. Our screening is built to find the ones that fit your story.

Source: Deloitte family office research.

Global family-office assets under management$5.5T
Five-year AuM growth+67%
Projected AuM by 2030$9T
Research

Independent research for investors who don’t read bank coverage.

For companies of any size. It gives investors a ready reason to take the meeting.

BloombergFactSetS&P Capital IQAlphaSenseLSEG Refinitiv
3,000+

research subscribers, plus distribution through the major terminals, so coverage shows up where investors already look.

Research may be issuer-sponsored; each report carries its own disclosures.

Companies

Companies we’ve introduced to new investors.

NYSE: HII
electroCoreNASDAQ: ECOR
PDS BiotechnologyNASDAQ: PDSB
CleneNASDAQ: CLNN
Achieve Life SciencesNASDAQ: ACHV
MovanoNASDAQ: MOVE
Lucid DiagnosticsNASDAQ: LUCD
PAVmedNASDAQ: PAVM
Xtant MedicalNYSE American: XTNT
Engage us

If you’re not appearing, you’re disappearing.

Tell us about your company and who you’re trying to reach. We’ll tell you honestly whether we can help.

309 East Paces Ferry Road NE, Suite 400
Atlanta, GA 30305
877.889.1972
investorrelations@cg.capital